Stay updated on Sitravatinib Combo with PD-(L)1 in Urothelial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib Combo with PD-(L)1 in Urothelial Carcinoma Clinical Trial page.

Latest updates to the Sitravatinib Combo with PD-(L)1 in Urothelial Carcinoma Clinical Trial page
- Check2 days agoChange DetectedNo additions or deletions were listed for this page, so the content remains as published. The provided data shows no textual changes to assess in context.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing Revision: v3.6.4, indicating a minor version update to the page. This reflects internal maintenance rather than substantive changes to the study information.SummaryDifference0.0%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedRevision updated from v3.6.3 to v3.6.4 on the page, reflecting a minor internal update to the page's software/versioning rather than changes to study content.SummaryDifference0.0%

- Check52 days agoChange DetectedThe revision label on the page updated from v3.6.2 to v3.6.3. This reflects a new release of the page’s software/content management update.SummaryDifference0.0%

- Check60 days agoChange DetectedFooter revision label updated to v3.6.2, replacing v3.6.0, indicating a site revision rather than changes to the study content.SummaryDifference0.0%

- Check74 days agoChange DetectedDifference0.3%

Stay in the know with updates to Sitravatinib Combo with PD-(L)1 in Urothelial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib Combo with PD-(L)1 in Urothelial Carcinoma Clinical Trial page.